| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11936-005-0037-8 |
| P698 | PubMed publication ID | 16004857 |
| P2093 | author name string | James B Meigs | |
| P2860 | cites work | A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors | Q45124693 |
| Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study | Q45256257 | ||
| Moderate-intensity physical activity and fasting insulin levels in women: the Cross-Cultural Activity Participation Study | Q47669769 | ||
| United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. | Q50109154 | ||
| Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. | Q50897068 | ||
| Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. | Q51557017 | ||
| Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. | Q51558893 | ||
| Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. | Q51570195 | ||
| Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. | Q54060454 | ||
| Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension | Q57085781 | ||
| Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) | Q73209707 | ||
| Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study | Q73715603 | ||
| Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes | Q74555870 | ||
| Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group | Q77223580 | ||
| Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study | Q77318021 | ||
| Trends in cardiovascular complications of diabetes | Q81053229 | ||
| Standards of medical care in diabetes | Q81195722 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators | Q28144781 | ||
| Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 | ||
| The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE> | Q28204197 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators | Q29547887 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group | Q29617736 | ||
| Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) | Q29618529 | ||
| Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group | Q29619460 | ||
| Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 | ||
| Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines | Q29619614 | ||
| Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group | Q29619877 | ||
| Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels | Q29620696 | ||
| Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial | Q29622926 | ||
| Smoking and diabetes | Q33764685 | ||
| MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial | Q33966645 | ||
| Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus | Q34142970 | ||
| Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Ph | Q34208058 | ||
| Thiazolidinediones | Q34346862 | ||
| Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. | Q34466568 | ||
| Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial | Q34502430 | ||
| Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome | Q35886214 | ||
| Diabetes and cardiovascular disease. The Framingham study | Q41509493 | ||
| Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects | Q41741973 | ||
| Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study | Q41840439 | ||
| Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial | Q43606926 | ||
| Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes | Q43666606 | ||
| Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol | Q43950414 | ||
| Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study | Q44155702 | ||
| Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes | Q44295713 | ||
| The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension | Q44611131 | ||
| Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity | Q44631783 | ||
| In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control | Q44745053 | ||
| Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study | Q44779335 | ||
| Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus | Q44786820 | ||
| Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus | Q44869418 | ||
| Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes | Q44909522 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | coronary artery disease | Q844935 |
| P304 | page(s) | 259-71 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | Current treatment options in cardiovascular medicine | Q27714743 |
| P1476 | title | Prevention of coronary heart disease in diabetes | |
| P478 | volume | 7 |
| Q46032945 | Involvement of NADPH oxidase in oxidized LDL-induced upregulation of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cells. | cites work | P2860 |
Search more.